{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:23:12Z","timestamp":1786990992883,"version":"build-2736575974"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.intimp.2024.111697","type":"journal-article","created":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T12:12:41Z","timestamp":1707999161000},"page":"111697","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Evaluation of interleukins (IL-1\u03b1, IL-1Ra, IL-12, IL-17A, IL-31, and IL-33) and chemokines (CXCL10 and CXCL16) in the serum of male patients with ankylosing spondylitis"],"prefix":"10.1016","volume":"129","author":[{"given":"Hanan Y.","family":"Muhsin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali Q.","family":"Khazaal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haneen M.","family":"Ismaeel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed H.","family":"Alosami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali H.","family":"Ad'hiah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2024.111697_b0005","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41413-019-0057-8","article-title":"Ankylosing spondylitis: etiology, pathogenesis, and treatments","volume":"7","author":"Zhu","year":"2019","journal-title":"Bone Res."},{"key":"10.1016\/j.intimp.2024.111697_b0010","first-page":"2759","article-title":"Ankylosing spondylitis - A review article","volume":"12","author":"Anantha Eashwar","year":"2019","journal-title":"Drug Invent. Today."},{"key":"10.1016\/j.intimp.2024.111697_b0015","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1177\/1759720X18773726","article-title":"Ankylosing spondylitis and axial spondyloarthritis: recent insights and impact of new classification criteria","volume":"10","author":"Proft","year":"2018","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"key":"10.1016\/j.intimp.2024.111697_b0020","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1002\/acr.24774","article-title":"Incidence of Ankylosing Spondylitis Among Male and Female United States Army Personnel","volume":"75","author":"Nelson","year":"2023","journal-title":"Arthritis Care Res."},{"key":"10.1016\/j.intimp.2024.111697_b0025","doi-asserted-by":"crossref","first-page":"e001888","DOI":"10.1136\/rmdopen-2021-001888","article-title":"Changes in ankylosing spondylitis incidence, prevalence and time to diagnosis over two decades","volume":"7","author":"Crossfield","year":"2021","journal-title":"RMD Open"},{"key":"10.1016\/j.intimp.2024.111697_b0030","doi-asserted-by":"crossref","first-page":"7694","DOI":"10.1038\/s41598-018-25933-4","article-title":"Trends in the prevalence and incidence of ankylosing spondylitis in South Korea, 2010\u20132015 and estimated differences according to income status","volume":"8","author":"Park","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.intimp.2024.111697_b0035","doi-asserted-by":"crossref","DOI":"10.1177\/1179544117751627","article-title":"Does HLA-B27 status influence ankylosing spondylitis phenotype?","volume":"11","author":"Akassou","year":"2018","journal-title":"Clin. Med. Insights Arthritis Musculoskelet. Disord."},{"key":"10.1016\/j.intimp.2024.111697_b0040","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.601518","article-title":"Spondyloarthritis and the Human Leukocyte Antigen (HLA)-B*27 Connection","volume":"12","author":"Kavadichanda","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2024.111697_b0045","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.biopha.2018.05.097","article-title":"Role of innate immune system in the pathogenesis of ankylosing spondylitis","volume":"105","author":"Vanaki","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.intimp.2024.111697_b0050","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/imm.13242","article-title":"New developments in our understanding of ankylosing spondylitis pathogenesis","volume":"161","author":"Voruganti","year":"2020","journal-title":"Immunology"},{"key":"10.1016\/j.intimp.2024.111697_b0055","doi-asserted-by":"crossref","first-page":"6008","DOI":"10.3390\/ijms20236008","article-title":"Cytokines in inflammatory disease","volume":"20","author":"Kany","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2024.111697_b0060","doi-asserted-by":"crossref","first-page":"e2004433","DOI":"10.1002\/advs.202004433","article-title":"Cytokines: From Clinical Significance to Quantification","volume":"8","author":"Liu","year":"2021","journal-title":"Adv. Sci."},{"key":"10.1016\/j.intimp.2024.111697_b0065","first-page":"1328","article-title":"The Interleukine-17 Cytokine Family: Role in Development and Progression of Spondyloarthritis","volume":"11","author":"Davydova","year":"2023","journal-title":"Current and Potential Therapeutic Inhibitors, Biomedicines."},{"key":"10.1016\/j.intimp.2024.111697_b0070","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24043957","article-title":"Cytokines in Spondyloarthritis and Inflammatory Bowel Diseases: From Pathogenesis to Therapeutic Implications","volume":"24","author":"Felice","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2024.111697_b0075","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1007\/s10067-020-05308-9","article-title":"Assessing rheumatologists\u2019 attitudes and utilization of classification criteria for ankylosing spondylitis and axial spondyloarthritis: a global effort","volume":"40","author":"Rich-Garg","year":"2021","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.intimp.2024.111697_b0080","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s10067-007-0755-2","article-title":"Defining disease status in ankylosing spondylitis: Validation and cross-cultural adaptation of the Arabic Bath Ankylosing Spondylitis Functional Index (BASFI), the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), and the Bath Ankylosing Spondy","volume":"27","author":"El Miedany","year":"2008","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.intimp.2024.111697_b0085","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3352\/jeehp.2021.18.17","article-title":"Sample size determination and power analysis using the G*Power software","volume":"18","author":"Kang","year":"2021","journal-title":"J. Educ. Eval. Health Prof."},{"issue":"2021","key":"10.1016\/j.intimp.2024.111697_b0090","doi-asserted-by":"crossref","first-page":"D605","DOI":"10.1093\/nar\/gkaa1074","article-title":"The STRING database in 2021: Customizable protein-protein networks, and functional characterization of user-uploaded gene\/measurement sets","volume":"49","author":"Szklarczyk","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.intimp.2024.111697_b0095","doi-asserted-by":"crossref","first-page":"25","DOI":"10.4097\/kja.21209","article-title":"Receiver operating characteristic curve: overview and practical use for clinicians","volume":"75","author":"Nahm","year":"2022","journal-title":"Korean J. Anesthesiol."},{"key":"10.1016\/j.intimp.2024.111697_b0100","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/cc3045","article-title":"Statistics review 14: Logistic regression","volume":"9","author":"Bewick","year":"2005","journal-title":"Crit. Care."},{"key":"10.1016\/j.intimp.2024.111697_b0105","doi-asserted-by":"crossref","first-page":"8659302","DOI":"10.1155\/2019\/8659302","article-title":"Implication of IL-17 in Bone Loss and Structural Damage in Inflammatory Rheumatic Diseases","volume":"2019","author":"Le Goff","year":"2019","journal-title":"Mediators Inflamm."},{"key":"10.1016\/j.intimp.2024.111697_b0110","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1007\/s10067-020-05545-y","article-title":"Efficacy and safety of interleukin-17A inhibitors in patients with ankylosing spondylitis: a systematic review and meta-analysis of randomized controlled trials","volume":"40","author":"Wang","year":"2021","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.intimp.2024.111697_b0115","first-page":"131","article-title":"Association of Serum Interleukin-17 and Interleukin-23 Levels with Disease Activity, Function, Mobility, Enthesitis Index in Patients with Ankylosing Spondylitis, Aktuelle","volume":"48","author":"Beyazal","year":"2023","journal-title":"Rheumatol."},{"key":"10.1016\/j.intimp.2024.111697_b0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.102760","article-title":"Exploring IL-17 in spondyloarthritis for development of novel treatments and biomarkers","volume":"20","author":"Groen","year":"2021","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.intimp.2024.111697_b0125","doi-asserted-by":"crossref","first-page":"6194864","DOI":"10.1155\/2020\/6194864","article-title":"Role of Chemokine (C-X-C Motif) Ligand 10 (CXCL10) in Renal Diseases","volume":"2020","author":"Gao","year":"2020","journal-title":"Mediators Inflamm."},{"key":"10.1016\/j.intimp.2024.111697_b0130","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.cyto.2016.01.012","article-title":"Circulating levels of Th1 and Th2 chemokines in patients with ankylosing spondylitis","volume":"81","author":"Wang","year":"2016","journal-title":"Cytokine"},{"key":"10.1016\/j.intimp.2024.111697_b0135","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.biopha.2018.01.108","article-title":"Immune cells involved in the pathogenesis of ankylosing spondylitis","volume":"100","author":"Rezaiemanesh","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.intimp.2024.111697_b0140","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.996103","article-title":"Joint together: The etiology and pathogenesis of ankylosing spondylitis","volume":"13","author":"Xiong","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2024.111697_b0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13075-023-03044-4","article-title":"Quantitative proteomic screening uncovers candidate diagnostic and monitoring serum biomarkers of ankylosing spondylitis","volume":"25","author":"Hwang","year":"2023","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.intimp.2024.111697_b0150","doi-asserted-by":"crossref","first-page":"305","DOI":"10.2174\/1389201021666200302104418","article-title":"Fc Fusion Protein Downregulates RANKL\/OPG Ratio by Inhibiting CXCL16\/CXCR6 in Active Ankylosing Spondylitis","volume":"22","author":"Zhang","year":"2020","journal-title":"Curr. Pharm. Biotechnol."},{"key":"10.1016\/j.intimp.2024.111697_b0155","doi-asserted-by":"crossref","first-page":"5145","DOI":"10.4049\/jimmunol.166.8.5145","article-title":"Expression Cloning of the STRL33\/BONZO\/TYMSTR Ligand Reveals Elements of CC, CXC, and CX3C Chemokines","volume":"166","author":"Wilbanks","year":"2001","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2024.111697_b0160","doi-asserted-by":"crossref","first-page":"e301","DOI":"10.1002\/ctm2.301","article-title":"Activation of CXCL16\/CXCR6 axis aggravates cardiac ischemia\/reperfusion injury by recruiting the IL-17a-producing CD1d + T cells","volume":"11","author":"Wang","year":"2021","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.intimp.2024.111697_b0165","doi-asserted-by":"crossref","first-page":"3490","DOI":"10.3390\/ijms22073490","article-title":"The role of cxcl16 in the pathogenesis of cancer and other diseases","volume":"22","author":"Korbecki","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2024.111697_b0170","first-page":"153","article-title":"Predictive significance of CXCL8, CXCL10 and CXCL16 in juvenile idiopathic and rheumatoid arthritis Iraqi patients, Egypt","volume":"42","author":"Muhsin","year":"2020","journal-title":"Rheumatol."},{"key":"10.1016\/j.intimp.2024.111697_b0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.110530","article-title":"Role of the CXCR6\/CXCL16 axis in autoimmune diseases","volume":"121","author":"Bao","year":"2023","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.intimp.2024.111697_b0180","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-018-25722-z","article-title":"Increase in Il-31 Serum Levels Is Associated with Reduced Structural Damage in Early Axial Spondyloarthritis","volume":"8","author":"Rosine","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.intimp.2024.111697_b0185","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.cytogfr.2008.08.003","article-title":"Structures and biological functions of IL-31 and IL-31 receptors","volume":"19","author":"Zhang","year":"2008","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.intimp.2024.111697_b0190","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/all.13239","article-title":"Emerging role of interleukin-31 and interleukin-31 receptor in pruritus in atopic dermatitis, Allergy Eur","volume":"73","author":"Furue","year":"2018","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.intimp.2024.111697_b0195","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.3390\/ijms21041239","article-title":"IL-33\/IL-31 axis in osteoporosis","volume":"21","author":"De Martinis","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2024.111697_b0200","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1111\/all.14791","article-title":"Interleukin-31: The \u201citchy\u201d cytokine in inflammation and therapy, Allergy Eur","volume":"76","author":"Datsi","year":"2021","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.intimp.2024.111697_b0205","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/imr.12624","article-title":"Introduction to the interleukin-1 family of cytokines and receptors: Drivers of innate inflammation and acquired immunity","volume":"281","author":"Dinarello","year":"2018","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.intimp.2024.111697_b0210","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/s41584-022-00797-1","article-title":"IL-1 and autoinflammatory disease: biology, pathogenesis and therapeutic targeting","volume":"18","author":"Broderick","year":"2022","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.intimp.2024.111697_b0215","doi-asserted-by":"crossref","unstructured":"A.S. Jaber, A.H. Ad\u2019hiah, A novel signature of interleukins 36\u03b1, 37, 38, 39 and 40 in ankylosing spondylitis, Cytokine. 162 (2023) 156117. 10.1016\/j.cyto.2022.156117.","DOI":"10.1016\/j.cyto.2022.156117"},{"key":"10.1016\/j.intimp.2024.111697_b0220","doi-asserted-by":"crossref","first-page":"E432","DOI":"10.1097\/RHU.0000000000001515","article-title":"Going Further: Comprehensive Disease Control of Rheumatoid Arthritis, Targeting Cytokines and Chemokines","volume":"27","author":"Chavarria-Avila","year":"2021","journal-title":"J Clin. Rheumatol."},{"key":"10.1016\/j.intimp.2024.111697_b0225","first-page":"40","article-title":"The IL-12 family of cytokines in infection, inflammation and autoimmune disorders, Inflamm. Allergy - Drug","volume":"8","author":"Gee","year":"2009","journal-title":"Targets"},{"key":"10.1016\/j.intimp.2024.111697_b0230","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.cyto.2015.01.030","article-title":"Interleukin 12 (IL-12) family cytokines: Role in immune pathogenesis and treatment of CNS autoimmune disease","volume":"75","author":"Sun","year":"2015","journal-title":"Cytokine"},{"key":"10.1016\/j.intimp.2024.111697_b0235","doi-asserted-by":"crossref","unstructured":"M. Cherciu, L.I. Cherciu, M. Bojinca, T. Serban, C. Bara, O.M. Popa, Interleukin (Il) 12, Il-23 and Il-23 Receptor in Ankylosing Spondylitis Pathophysiology, Rom. J. Rheumatol. 24 (2015) 5\u201313. 10.37897\/rjr.2015.1.1.","DOI":"10.37897\/RJR.2015.1.1"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924002157?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924002157?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T04:46:41Z","timestamp":1769230001000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576924002157"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":47,"alternative-id":["S1567576924002157"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2024.111697","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of interleukins (IL-1\u03b1, IL-1Ra, IL-12, IL-17A, IL-31, and IL-33) and chemokines (CXCL10 and CXCL16) in the serum of male patients with ankylosing spondylitis","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2024.111697","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"111697"}}